X0306 4 2013-04-03 false 0000911326 SYNAGEVA BIOPHARMA CORP GEVA 0001532218 Patel Sanj K 128 SPRING STREET, SUITE 520 LEXINGTON MA 02421 true true false false President & CEO Common Stock 286 I Held by Abbey Road Investment Group Common Stock 2013-04-03 4 M false 9464 0.95 A 10495 D Common Stock 2013-04-03 4 M false 7000 0.95 A 17495 D Common Stock 2013-04-03 4 S false 10206 51.085 D 7289 D Common Stock 2013-04-03 4 S false 4358 52.551 D 2931 D Common Stock 2013-04-03 4 S false 1500 53.373 D 1431 D Common Stock 2013-04-03 4 S false 400 54.443 D 1031 D Common Stock 2013-04-04 4 M false 21931 0.95 A 22962 D Common Stock 2013-04-04 4 S false 18580 50.121 D 4382 D Common Stock 2013-04-04 4 S false 2151 50.72 D 2231 D Common Stock 2013-04-04 4 S false 1200 51.64 D 1031 D Stock Option (Right to Buy) 0.95 2013-04-03 4 M false 9464 0 D 2019-07-01 Common Stock 9464 31794 D Stock Option (Right to Buy) 0.95 2013-04-03 4 M false 7000 0 D 2019-12-15 Common Stock 7000 95032 D Stock Option (Right to Buy) 0.95 2013-04-04 4 M false 21931 0 D 2019-12-15 Common Stock 21931 73101 D The stock option exercise and sale of shares of common stock ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 5, 2012. The stock option granted the reporting person an option to purchase 396,070 Shares. 25% of such Shares vested and became exercisable on 07/01/2010, and 1/36 of the remainder of such Shares vest and become exercisable monthly thereafter. The stock option granted the reporting person an option to purchase 117,220 Shares. 25% of such Shares vested and became exercisable on 09/25/2010, and 1/36 of the remainder of such Shares vest and become exercisable monthly thereafter. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $50.59 to $51.51. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $51.86 to $52.78. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $52.95 to $53.63. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $54.20 to $54.65. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $49.485 to $50.48. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $50.481 to $51.46. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $51.48 to $51.86. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. /s/ Sanj K. Patel 2013-04-05